Project Grant R21CA300631
Award Date
4/10/25
Completion Date
3/31/27
Dollars Obligated
$225K
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
Texas, USA
Similar Awards
The National Cancer Institute (NCI) awarded a $431,968 Project Grant under the Cancer Biology Research program (CFDA 93.396) to Baylor College of Medicine. The grant, with a performance period from August 15, 2024 to July 31, 2029, will fund research to elucidate how the oncogenic MYCN gene drives metabolic reprogramming in high-risk neuroblastoma, leading to an immunosuppressive tumor microenvironment. The researchers aim to modulate the metabolic environment of neuroblastoma tumors to...
This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) supports research to understand the mechanisms by which the MYCN oncogene promotes an immunosuppressive tumor microenvironment in high-risk neuroblastoma. The $635,173 award to Trustees of Boston University, effective December 1, 2024 through November 30, 2029, will leverage zebrafish models and...
This $576,659 Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research to investigate tumor and host immune signatures associated with health disparities in outcomes following immunotherapy for pediatric neuroblastoma. The overarching goal is to utilize biological samples from a Children's Oncology Group clinical trial to perform tumor microenvironment and host immune analyses across patients, with a focus on identifying markers that...
This $125,000 Project Grant awarded by the National Institute of General Medical Sciences (NIGMS) under CFDA 93.859 Biomedical Research and Research Training program supports research to characterize the tumor immune microenvironment (TIME) and metastatic progression in triple negative breast cancer (TNBC). The award to Baylor College of Medicine aims to spatially profile the TIME of lung and liver metastases following treatment with anti-CSF1R, chemotherapy, and anti-PD1 therapy. The goal is to...
This $452,549 Project Grant award from the National Cancer Institute's Cancer Treatment Research program (CFDA 93.395) supports research by Emory University to comprehensively characterize the intrinsic molecular features and extrinsic tumor microenvironment of MYC-driven osteosarcoma. The key objectives are to: Identify the cross-species molecular signatures and cell-cell communications in MYC-hyperactivated human and murine osteosarcoma tumors. This will involve profiling intrinsic and...
The National Cancer Institute (NCI) awarded a $208,415 Project Grant under the Cancer Research Manpower (CFDA 93.398) program to Duke University. The grant, awarded on August 1, 2024, supports research to investigate the mechanisms by which residual tumor cells evade the immune system after treatment with oncogene-targeted therapies. The research project aims to uncover how residual tumor cells upregulate "don't eat me" markers like CD47 to avoid clearance by macrophages, a key...
The National Cancer Institute (NCI) awarded the University of Chicago a $377,870 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to develop and validate highly stable and potent synthetic transcriptional repressors (STRs) that can directly target the oncogenic transcription factor MYC. The project aims to structurally and biochemically optimize the STRs, enhance their cellular and pharmacological delivery, and evaluate their efficacy in inhibiting MYC-driven cancer...
This federal Project Grant award from the National Cancer Institute (NCI), under the Cancer Cause and Prevention Research program (CFDA 93.393), supports research to investigate mechanisms underlying T-cell dysfunction within the tumor microenvironment. The $103,948 award will be used by the Sloan-Kettering Institute for Cancer Research to conduct two primary research aims: 1) Determine how local amino acid availability impacts the exhausted T-cell proteome and T-cell function, and 2) Examine...
The National Cancer Institute (NCI) awarded a $415,257 Project Grant (CFDA 93.395 - Cancer Treatment Research) to The Methodist Hospital Research Institute (HMRI) in Houston, TX. The grant, running from July 1, 2024 to June 30, 2026, will fund research to explore the role of stress granules in chimeric antigen receptor (CAR) T-cell exhaustion and how targeting upstream metabolic stress regulators can improve CAR-T cell function and longevity. The project aims to provide novel insights into...
The National Cancer Institute (NCI) awarded a $1,217,906 Project Grant under the Cancer Biology Research (CFDA 93.396) federal grant program to Cosmyc Inc. in Dover, DE. The award, with a project period from June 2024 to May 2025, will support research aimed at understanding the fundamental biological mechanisms underlying cancer development, progression, and potential treatment interventions, with a focus on the inhibition of MYC:TRRAP interaction in cancer. The research is expected to...